SEC Form 4 · accession 0001628280-26-060491
Veradermics, Inc · MANE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Hollander
Officer — Chief R&D Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001827635
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2026 | A | 9,650 | $0.00 | A | 9,650 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $97.51 | Sep 1, 2026 | A | 19,300 | A | — | Sep 1, 2036 | Common Stock | 19,300 | 19,300 | D |
Explanation of responses
- F1These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service.
- F2The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.